Prelude Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Prelude Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,500	Closed	-$1.45M	–	1492
2023 Q3	$1.45M	Buy	12,500 +6,300	+102%	+$677K	0.09%	246
2023 Q2	$638K	Buy	+6,200	New	+$654K	0.04%	391
2023 Q1	–	Sell	-8,000	Closed	-$910K	–	1690
2022 Q4	$910K	Buy	+8,000	New	+$664K	0.05%	409
2020 Q4	–	Sell	-3,522	Closed	-$274K	–	2299
2020 Q3	$274K	Buy	+3,522	New	+$242K	0.01%	593
2014 Q3	–	Sell	-2,000	Closed	-$32K	–	2264
2014 Q2	$32K	Buy	+2,000	New	+$28.5K	﹤0.01%	1626

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's HZNP Position: Q4 2023 in Review

Prelude Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 135,854 shares — an estimated $15.7M sold.

Prelude Capital Management first reported a position in HZNP in Q2 2014 and held it in 21 quarters. The position peaked at $16.6M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Prelude Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Prelude Capital Management sold 135,854 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $15.7M.
Prelude Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 21 quarters.
Prelude Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $16.6M in Q1 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.